
Internet Explorer is no longer supported by this website. - jnj
Oct 25, 2022horsham, pa., october 25, 2022 - the janssen pharmaceutical companies of johnson & johnson announced today that the u.s. food and drug administration (fda) approved tecvayli™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a …